Researchers decode new antibiotic
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic. (Source: World Pharma News)
Source: World Pharma News - August 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
U.S. FDA Approves ABRYSVO ™, Pfizer & #039;s vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. (Source: World Pharma News)
Source: World Pharma News - August 23, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market. (Source: World Pharma News)
Source: World Pharma News - August 22, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
DNA repair discoveries hold promise for new approaches to cancer treatment
DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.
Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair. (Source: World Pharma News)
Source: World Pharma News - August 21, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
AbbVie announces European Commission approval of AQUIPTA ® (atogepant) for the preventive treatment of migraine in adults
AbbVie (NYSE: ABBV) announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine. (Source: World Pharma News)
Source: World Pharma News - August 18, 2023 Category: Pharmaceuticals Tags: Featured AbbVie Business and Industry Source Type: news
Adherence to a Mediterranean lifestyle associated with lower risk of all-cause and cancer mortality
People who adhere to a Mediterranean lifestyle - which includes a diet rich in fruits, vegetables, and whole grains; healthy eating habits like limiting added salts and sugars; and habits promoting adequate rest, physical activity, and socialization - have a lower risk of all-cause and cancer mortality, according to a new study led by La Universidad Autónoma de Madrid and Harvard T.H. Chan School of Public Health. (Source: World Pharma News)
Source: World Pharma News - August 17, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New early Alzheimer ’s treatment shows Improvement in cognition
Dr. Heather Sandison, a leading expert in Alzheimer's Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer's Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline. The study is the second to employ a multimodal, individualized care plan and offers further hope for managing and potentially reversing cognitive impairment. (Source: World Pharma News)
Source: World Pharma News - August 16, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Cancer-infecting virus & #039;warms up & #039; cold tumors and improves immunotherapy
Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, according to a new study in the Journal of Experimental Medicine led by University of Pittsburgh and UPMC researchers. The results pave the way for clinical trials combining oncolytic viruses with immunotherapy. (Source: World Pharma News)
Source: World Pharma News - August 15, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Pfizer & #039;s ELREXFIO ™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Source: World Pharma News)
Source: World Pharma News - August 14, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
A medication used for heart conditions improves the efficacy of current treatments for melanoma in mouse models
A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d'Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease. (Source: World Pharma News)
Source: World Pharma News - August 11, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
Bayer today announced two-year (96 weeks) topline results of the pivotal clinical trial PULSAR in patients with neovascular (wet) age-related macular degeneration (nAMD). The data reinforce sustained vision gains with unprecedented extended treatment intervals of aflibercept 8 mg reaching up to 24 weeks with efficacy and safety comparable to the current standard of care Eylea™ (aflibercept 2 mg) with fixed intervals of 8 weeks. (Source: World Pharma News)
Source: World Pharma News - August 10, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Stem cell therapy rescues symptoms of Alzheimer & #039;s disease
In the ongoing search for a cure for Alzheimer's disease, a burgeoning branch of medicine is bringing new hope. Stem cell therapies are already being used to treat various cancers and disorders of the blood and immune system. In a new proof-of-concept study, scientists at University of California San Diego show stem cell transplants may also be a promising therapeutic against Alzheimer's. (Source: World Pharma News)
Source: World Pharma News - August 9, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study
An antibody in single-chain fragment variable (scFv) format that binds to the powerful opioid carfentanil was shown to reverse signs of carfentanil overdose in preclinical tests conducted by scientists at Scripps Research.
Carfentanil is a variant of the synthetic opioid fentanyl, and about 100 times as potent as its chemical cousin. (Source: World Pharma News)
Source: World Pharma News - August 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA approves first oral treatment for postpartum depression
The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. (Source: World Pharma News)
Source: World Pharma News - August 7, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Bill & Melinda Gates Foundation, Children & #039;s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries
To help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation (CIFF), Pfizer and Becton, Dickinson & Company (BD) announced the expansion of their nearly decade-long collaboration. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer's injectable contraceptive, Sayana® Press (medroxyprogesterone acetate)(1) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030. (Source: World Pharma News)
Source: World Pharma News - August 4, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
